HRP20211908T1 - Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa - Google Patents
Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa Download PDFInfo
- Publication number
- HRP20211908T1 HRP20211908T1 HRP20211908TT HRP20211908T HRP20211908T1 HR P20211908 T1 HRP20211908 T1 HR P20211908T1 HR P20211908T T HRP20211908T T HR P20211908TT HR P20211908 T HRP20211908 T HR P20211908T HR P20211908 T1 HRP20211908 T1 HR P20211908T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- cnp variant
- seq
- nos
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu u postupku i) liječenja osteoartritisa; ii) povećanja rasta hrskavice kod subjekta s osteoartritisom; iii) usporavanje degeneracije hrskavice; iv) ublažavanje simptoma osteoartritisa; v) povećanje motoričkih vještina ili pokretljivosti kod pacijenta s osteoartritisom; vi) inhibiranja degeneracije pokretljivosti kod pacijenta s osteoartritisom; vii) povećanje raspona pokreta u zahvaćenom zglobu subjekta koji ima osteoartritis; viii) smanjenje ukočenosti u zahvaćenom zglobu subjekta koji ima osteoartritis; ix) smanjenje sinovijalne upale kod subjekta; ili x) sprječavanje nastanka osteoartritisa, kod subjekta kojem je to potrebno, pri čemu se CNP varijanta primjenjuje intraartikularno.
2. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 1, naznačena time što je osteoartritis primarni osteoartritis ili sekundarni artritis.
3. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 2, naznačena time što se CNP varijanta primjenjuje nakon što je nastupila degeneracija hrskavice.
4. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 2, naznačena time što se CNP varijanta primjenjuje kao odgovor na ozljedu ili traumu zgloba.
5. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 4, naznačena time što se CNP varijanta primjenjuje unutar jednog mjeseca od ozljede ili traume zgloba.
6. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema bilo kojem od prethodnih patentnih zahtjeva naznačena time što pripravak koji sadrži CNP varijantu daje 3 puta tjedno, dva puta tjedno, jednom tjedno ili jednom u dva tjedna.
7. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 1, naznačena time što se povećanje rasta hrskavice ili usporavanje degeneracije hrskavice opaža u zglobu subjekta.
8. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 7, naznačena time što je zglob odabran iz skupine koja se sastoji od koljena, ramena, lakta, prsta, šake, zapešća, kuka, vrata, kralježnice i donjeg dijela leđa.
9. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 1, naznačena time što se oštećenje ili rast hrskavice analizira smrću/gubitkom kondrocita, gubitkom proteoglikana (PG), ili gubitkom kolagena ili fibrilacijom.
10. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema bilo kojem od prethodnih patentnih zahtjeva naznačena time što CNP varijanta nadalje sadrži farmaceutski prihvatljivu pomoćnu tvar, nosač ili razrjeđivač.
11. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 10, naznačena time što je CNP varijanta u liofiliziranoj formulaciji pripremljenoj od formulacije koja sadrži pufer limunska kiselina/citrat ili pufer octena kiselina/acetat koji ima pH od 4 do 6.
12. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema bilo kojem od prethodnih patentnih zahtjeva naznačena time što dalje uključuje primjenu drugog sredstva, po izboru pri čemu je drugo sredstvo odabrano iz skupine koju čine protuupalno sredstvo, NSAID, kortikosteroid i hijaluronska kiselina.
13. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 1, naznačena time što je raspon pokreta zahvaćenog zgloba određen mjerenjem fleksije kuka, ekstenzije kuka, abdukcije kuka, adukcije kuka, fleksije koljena ili ekstenzije koljena.
14. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što je identificirano da subjekt ima povećane razine najmanje jednog biomarkera povezanog s hrskavicom, po izboru pri čemu je najmanje jedan biomarker povezan s hrskavicom odabran iz skupine koja se sastoji od CNP, cGMP, propeptida kolagena tipa II i njegovih fragmenata, kolagena tipa II i njegovih fragmenata, osteokalcina, nuklearnog antigena proliferirajućih stanica (PCNA), propeptida prokolagena tipa I (PINP) i njegovih fragmenata, kolagena tipa I i njegovih fragmenata, i agrekan kondroitin sulfata.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562264682P | 2015-12-08 | 2015-12-08 | |
| PCT/US2016/065520 WO2017100400A2 (en) | 2015-12-08 | 2016-12-08 | Use of c-type natriuretic peptide variants to treat osteoarthritis |
| EP16852866.9A EP3386531B1 (en) | 2015-12-08 | 2016-12-08 | Use of c-type natriuretic peptide variants to treat osteoarthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211908T1 true HRP20211908T1 (hr) | 2022-03-04 |
Family
ID=59013378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211908TT HRP20211908T1 (hr) | 2015-12-08 | 2016-12-08 | Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11202819B2 (hr) |
| EP (2) | EP3386531B1 (hr) |
| JP (1) | JP7104625B2 (hr) |
| KR (1) | KR102941538B1 (hr) |
| CN (1) | CN108697766A (hr) |
| AU (2) | AU2016365751B2 (hr) |
| CA (1) | CA3007315A1 (hr) |
| DK (1) | DK3386531T3 (hr) |
| ES (1) | ES2901769T3 (hr) |
| HR (1) | HRP20211908T1 (hr) |
| HU (1) | HUE057083T2 (hr) |
| IL (1) | IL259690B2 (hr) |
| MX (1) | MX2018006986A (hr) |
| PL (1) | PL3386531T3 (hr) |
| PT (1) | PT3386531T (hr) |
| RU (1) | RU2759679C2 (hr) |
| WO (1) | WO2017100400A2 (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3008017C (en) | 2016-01-08 | 2024-01-02 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| AU2017205688C1 (en) | 2016-01-08 | 2022-03-10 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
| NZ743488A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low initial npr-b activity |
| US10835578B2 (en) | 2016-01-08 | 2020-11-17 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with large carrier moieties |
| AU2017205694B2 (en) | 2016-01-08 | 2022-05-26 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low NPR-C binding |
| AU2017205690B2 (en) | 2016-01-08 | 2022-04-28 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with increased NEP stability |
| HRP20230385T1 (hr) | 2016-09-29 | 2023-06-23 | Ascendis Pharma Growth Disorders A/S | Kombinirana terapija sa cnp agonistima s kontroliranim oslobađanjem |
| CN112752556A (zh) * | 2018-04-27 | 2021-05-04 | 雷米生物科学公司 | 新的医疗装置、递送运载体及其制造 |
| EP3923906A1 (en) * | 2019-02-11 | 2021-12-22 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of cnp conjugates |
| JP7837333B2 (ja) * | 2020-11-25 | 2026-03-30 | プロリンクス エルエルシー | Ｃ－ナトリウム利尿ペプチドの徐放性ヒドロゲルコンジュゲート |
| US20240238428A1 (en) * | 2021-05-11 | 2024-07-18 | Texas Tech University System | Targeted selenium conjugates as countermeasures for viral and cellular pathogens |
| CN119013035A (zh) * | 2021-12-07 | 2024-11-22 | 生物马林药物股份有限公司 | 骨相关病症的c型利钠肽疗法 |
| US12077561B2 (en) | 2022-11-02 | 2024-09-03 | Novo Nordisk A/S | CNP compounds |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| JP2026510974A (ja) | 2023-03-20 | 2026-04-10 | アセンディス ファーマ グロース ディスオーダーズ エー／エス | 軟骨形成不全症のヒト対象における胸腰椎奇形の治療の方法 |
| KR20250098109A (ko) * | 2023-12-21 | 2025-07-01 | 주식회사 펩트론 | 나트륨이뇨 펩타이드 유사체 및 이의 용도 |
| CN117801123B (zh) * | 2024-02-29 | 2024-05-03 | 天津凯莱英生物科技有限公司 | 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| JP2809533B2 (ja) | 1991-01-31 | 1998-10-08 | 壽之 松尾 | Ｃｎｐ類似体ペプチド |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| WO2005094889A1 (ja) * | 2004-03-31 | 2005-10-13 | Chugai Seiyaku Kabushiki Kaisha | 関節炎症治療剤又は予防剤 |
| EP3620530A1 (en) * | 2004-03-31 | 2020-03-11 | Kazuwa Nakao | Composition for increasing body height |
| EP2217620A2 (en) | 2007-11-21 | 2010-08-18 | BioMarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
| HUE032582T2 (en) | 2009-05-20 | 2017-09-28 | Biomarin Pharm Inc | Variants of c-type natriuretic peptide |
| EP2658979B1 (en) * | 2010-12-27 | 2018-02-14 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
-
2016
- 2016-12-08 EP EP16852866.9A patent/EP3386531B1/en active Active
- 2016-12-08 ES ES16852866T patent/ES2901769T3/es active Active
- 2016-12-08 HR HRP20211908TT patent/HRP20211908T1/hr unknown
- 2016-12-08 US US15/779,049 patent/US11202819B2/en active Active
- 2016-12-08 WO PCT/US2016/065520 patent/WO2017100400A2/en not_active Ceased
- 2016-12-08 HU HUE16852866A patent/HUE057083T2/hu unknown
- 2016-12-08 KR KR1020187019166A patent/KR102941538B1/ko active Active
- 2016-12-08 EP EP21202207.3A patent/EP4019038A3/en active Pending
- 2016-12-08 DK DK16852866.9T patent/DK3386531T3/da active
- 2016-12-08 CA CA3007315A patent/CA3007315A1/en active Pending
- 2016-12-08 MX MX2018006986A patent/MX2018006986A/es unknown
- 2016-12-08 JP JP2018530079A patent/JP7104625B2/ja active Active
- 2016-12-08 RU RU2018124600A patent/RU2759679C2/ru active
- 2016-12-08 PL PL16852866T patent/PL3386531T3/pl unknown
- 2016-12-08 CN CN201680081329.2A patent/CN108697766A/zh active Pending
- 2016-12-08 PT PT168528669T patent/PT3386531T/pt unknown
- 2016-12-08 AU AU2016365751A patent/AU2016365751B2/en active Active
-
2018
- 2018-05-29 IL IL259690A patent/IL259690B2/en unknown
-
2021
- 2021-12-03 US US17/541,992 patent/US12214015B2/en active Active
-
2024
- 2024-03-21 AU AU2024201852A patent/AU2024201852A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180088459A (ko) | 2018-08-03 |
| PT3386531T (pt) | 2021-12-29 |
| ES2901769T3 (es) | 2022-03-23 |
| IL259690B (en) | 2022-10-01 |
| JP2019505486A (ja) | 2019-02-28 |
| EP3386531B1 (en) | 2021-10-13 |
| AU2016365751A1 (en) | 2018-06-21 |
| IL259690A (en) | 2018-07-31 |
| HUE057083T2 (hu) | 2022-04-28 |
| US12214015B2 (en) | 2025-02-04 |
| KR102941538B1 (ko) | 2026-03-19 |
| US20190247467A1 (en) | 2019-08-15 |
| RU2018124600A (ru) | 2020-01-13 |
| CN108697766A (zh) | 2018-10-23 |
| RU2759679C2 (ru) | 2021-11-16 |
| AU2016365751B2 (en) | 2023-12-21 |
| JP7104625B2 (ja) | 2022-07-21 |
| EP3386531A2 (en) | 2018-10-17 |
| MX2018006986A (es) | 2018-09-05 |
| RU2018124600A3 (hr) | 2020-01-13 |
| RU2021132347A (ru) | 2022-03-24 |
| DK3386531T3 (da) | 2022-01-03 |
| EP4019038A2 (en) | 2022-06-29 |
| PL3386531T3 (pl) | 2022-02-28 |
| CA3007315A1 (en) | 2017-06-15 |
| US11202819B2 (en) | 2021-12-21 |
| WO2017100400A2 (en) | 2017-06-15 |
| EP4019038A3 (en) | 2022-09-28 |
| AU2024201852A1 (en) | 2024-04-11 |
| WO2017100400A3 (en) | 2017-10-26 |
| IL259690B2 (en) | 2023-02-01 |
| US20220160836A1 (en) | 2022-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018124600A (ru) | Применение вариантов натрийуретического пептида типа с для лечения остеоартрита | |
| JP2019505486A5 (hr) | ||
| Oddis et al. | A subluxing arthropathy associated with the anti‐Jo‐1 antibody in polymyositis/dermatomyositis | |
| HRP20200268T1 (hr) | Pripravci antisklerotinskih antitijela u visokim koncentracijama | |
| HRP20210277T1 (hr) | Pripravak za kontroliranu stimulaciju jajnika | |
| PH12019501900A1 (en) | Treatment of hidradenitis suppurativa | |
| CN103622013A (zh) | 一种供关节炎患者食用含骨胶原肽的食品配方 | |
| HRP20140888T1 (hr) | Humana monoklonalna protutijela za humani il-4 | |
| HRP20241491T1 (hr) | Pripravci i metode za liječenje homocistinurije | |
| Bettany-Saltikov et al. | Ergonomically designed kneeling chairs are they worth it?: Comparison of sagittal lumbar curvature in two different seating postures | |
| ES2579828T3 (es) | Composición para la prevención y el tratamiento de la artritis reumatoide | |
| Luo et al. | Finite element analysis of the biomechanical effects of manipulation of lower limb hyperextension on the sacroiliac joint | |
| Habibi et al. | Idiopathic chondrolysis in a child: think beyond JIA. | |
| Oleas-Santillán et al. | Anterior Hip Dislocation from post-injection gluteal muscular fibrosis: case report | |
| Panotopoulos et al. | Orthopedic interventions in patients with hemophilia | |
| Kumar | Dry gangrene of fingers and injection site pain following accidental intra-arterial injection: case report | |
| Barati et al. | Identifying base position for women’s thoracolumbar fascia ultrasound | |
| Abdulaziz et al. | A single center experience in biological therapy for the treatment of rheumatoid arthritis in Saudi Arabia | |
| CN204812197U (zh) | 一种老年人防摔骨折保护裤 | |
| Joseph et al. | Fractures in boys with Duchenne muscular dystrophy and their relationship to age | |
| Lee et al. | SAT0497 effect of raloxifene on osteoporosis and disease activity in postmenopausal female with rheumatic diseases | |
| Rodríguez et al. | Unilateral generalized morphea: a case and literature review | |
| Subrata Chakrabarti et al. | Rheumatoid arthritis in a case of primary biliary cirrhosis-an unusual association. | |
| MX2022004676A (es) | Composicion farmaceutica de extractos de plantas para tratar fibromialgia, artritis reumatoide, lupus y otras enfermedades autoinmunes. | |
| CN104490503A (zh) | 一种髋部护具 |